28 January 2010

Alizé seals diabetes collaboration with Lilly

Science|Business

Collaboration | Licensing

Metabolic diseases specialist Alizé Pharma has agreed a research collaboration and license option agreement with Eli Lilly and Company for its AZP-01 programme, in which it is developing ghrelin agonists for the treatment of Type II diabetes.

Lilly will pay an undisclosed upfront fee in return for an exclusive option to license the programme according to predefined terms. No other terms were disclosed.

Alizé of Lyon, France, says preclinical and preliminary clinical data suggest AZP-01 works through a novel mechanism of action that includes glucose and lipid-lowering effects, and also influences insulin-producing beta cells and increases sensitivity to insulin. As a result the compound may have the potential not only to control...

This page requires a subscription

This page is available to subscribers only. Please log in or subscribe and plug into the Science|Buisiness Network now, to get full access to all our news, events, business opportunities and subscriber-posting service.

We are the first independent news service connecting buyers and sellers of emerging technologies, across borders and across industries. We keep you ahead of the news on early-stage R&D investment – and provide opportunities for you to find and meet new investors, licensees and development partners, through our unique Science|Business Network of leading scientific institutions including the University of Cambridge, Karolinska Institute, ETH-Zürich and Imperial College London.

Be first into the next wave of technology. Click here to learn more

Note: Log in requires cookies to be enabled on your machine.

Lost your password? Enter your email address with no password and we'll send you a new password. Use this to log in, then, if you wish, click on the 'My Details' link at the top of the page to change your password.